Opinion
Video
Author(s):
The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML
Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC